← Leaderboards
Yubin Kang
Medical University Of South Carolina
$4,684,617
Attributed
$4,684,617
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $669.2K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,684,617 · 7
By mechanism
R01$1,807,653 · 1
R21$1,208,345 · 3
K08$648,945 · 1
U01$576,303 · 1
R56$443,371 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMolecularMissionDisabilityInnovationUnited States National Institutes Of HealthPublic HealthHematologic NeoplasmsMultiple MyelomaMouse ModelClinical TrialsPlayUnited StatesFda ApprovedPatient CareIn VitroIn VivoCaringRefractoryBaseMediatingPatient-Focused OutcomesIncidenceNovel Therapeutics
Grant awards (18)
Thioredoxin derivatives for radiation mitigation$576,303
U01 · FY2025 · AI · contact PI
Role of SLAMF7 in Racial Disparities in Myeloma$178,760
R21 · FY2024 · CA · contact PI
Role of SLAMF7 in Racial Disparities in Myeloma$234,835
R21 · FY2023 · CA · contact PI
Enhancing CAR T therapy in multiple myeloma$184,406
R21 · FY2023 · CA · contact PI
Thioredoxin, a novel agent for mitigating radiation-induced hematopoietic injury$443,371
R56 · FY2022 · HL · contact PI
Enhancing CAR T therapy in multiple myeloma$225,803
R21 · FY2022 · CA · contact PI
Effects of PPAR agonists on response to immunomodulatory agents in patients with multiple myeloma$175,088
R21 · FY2020 · CA · contact PI
Targeting sphingosine kinase 2 for the treatment of multiple myeloma$352,801
R01 · FY2019 · CA · contact PI
Effects of PPAR agonists on response to immunomodulatory agents in patients with multiple myeloma$209,453
R21 · FY2019 · CA · contact PI
Targeting sphingosine kinase 2 for the treatment of multiple myeloma$363,713
R01 · FY2018 · CA · contact PI
Targeting sphingosine kinase 2 for the treatment of multiple myeloma$363,713
R01 · FY2017 · CA · contact PI
Targeting sphingosine kinase 2 for the treatment of multiple myeloma$363,713
R01 · FY2016 · CA · contact PI
Targeting sphingosine kinase 2 for the treatment of multiple myeloma$363,713
R01 · FY2015 · CA · contact PI
Plerixafor for allogeneic hematopoietic stem cell transplantation$126,549
K08 · FY2015 · HL · contact PI
Plerixafor for allogeneic hematopoietic stem cell transplantation$127,683
K08 · FY2014 · HL · contact PI
Plerixafor for allogeneic hematopoietic stem cell transplantation$131,571
K08 · FY2013 · HL · contact PI
Plerixafor for allogeneic hematopoietic stem cell transplantation$131,571
K08 · FY2012 · HL · contact PI
Plerixafor for allogeneic hematopoietic stem cell transplantation$131,571
K08 · FY2011 · HL · contact PI